GlassScriptPhysician profile
Scott B Markowitz
NPI 1023057262
$1,452.05
in general payments reported to CMS, 2019-2025
18 companies · $267 in 2025
The $267 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $80.29 · 2021: $87.26 · 2022: $114 · 2023: $413 · 2024: $281 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $962.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $961.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $342.21 | 2019-2025 | |
| Glaxosmithkline, LLC. | $230.89 | 2021-2025 | Nucala |
| Kaleo, INC. | $213.04 | 2019-2024 | Auvi-Q |
| Optinose US, INC. | $94.86 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $69.39 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $68.51 | 2020-2022 | |
| Hikma Pharmaceuticals USA | $65.20 | 2023-2024 | Ryaltris |
| Alk-Abello, INC | $64.06 | 2019-2023 | Ragwitek, Odactra, Grastek |
| Stryker Corporation | $57.77 | 2019 | |
| Pfizer INC. | $57.75 | 2022-2023 | |
| Csl Behring | $33.12 | 2025 | Andembry |
| Phathom Pharmaceuticals, INC. | $27.17 | 2024 | Voquezna |
| Integra Lifesciences Corporation | $24.76 | 2024 | Acclarent Aera |
| Neurent Medical Limited | $23.43 | 2025 | Neuromark System, Neuromark Radiofrequency Console |
| Inspire Medical Systems, INC. | $23.31 | 2024 | Inspire |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $22.50 | 2023 | |
| Genentech USA, INC. | $19.01 | 2019 | |
| Smith+Nephew, INC. | $15.07 | 2024 | Rapid Rhino, Tula, Halo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Markowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.